As COVID-19 continues to prove itself a persistent global threat, Arbor Vita now offers direct COVID-19 testing for individuals and healthcare providers. In addition to our own in-house technology, we are continually seeking the best COVID-19 tests available to offer our customers, including detection of the new Delta/India subtype.
In this regard, Arbor Vita has collaborated with Yale University to bring you the SalivaDirect™ SARS-CoV-2 test. This FDA EUA-authorized test combines accurate, industry-standard RT-PCR technology with painless saliva sample collection.
All of our tests include SAME DAY RESULTS if your sample is received by 11am! Come learn about our CLIA-certified facilities and order your test today.
We’re Revolutionizing Diagnostics
No Woman Left Behind
Arbor Vita Corporation is devoted to protecting the health of women of all ages, races, and geographic locations. Current screening methods, such as the Pap smear and HPV DNA tests, detect cervical cell changes or the presence of (often harmless) HPV, but require a sophisticated processing protocol, limiting their efficacy and applicability—especially in rural areas. By contrast, the OncoE6™ Cervical Test can be used in both advanced settings and ones with limited infrastructure. It requires no refrigeration, is easy to administer (even via self-collection), and yields results in just over two hours. What’s more, our test can capture the same urgent, accurate results for women under 21 and over 60 who have been marginalized by conventional testing.
What Makes Us Special
Over 250 PDZ domain-containing proteins have been described in the human proteome. Irregular cell activation contributes to malignancies; PDZ proteins therefor comprise a new class of functional drug targets and diagnostic markers. We have a near-complete library of PDZ domains and have identified new interaction inhibitors, which will fuel the development of diagnostics and therapeutics.
Arbor Vita Corporation has unique capabilities in developing and manufacturing high- quality monoclonal antibodies (mAbs). This has enabled us to create a valuable and large library for the detection of select low-risk and all high-risk HPV oncoprotein E6/E7 types, specific influenza subtypes, as well as a variety of other proteins in infectious diseases and cancers.
Using PDZ domains and monoclonal antibodies, we have developed a pipeline of highly sensitive tests that can be used at the time and site of patient contact to detect specific disease protein markers. These tests (such as the OncoE6™ Cervical Test and the avian influenza detection tests), provide quick, actionable results and can be used in both advanced and remote healthcare settings.